sodium starch glycolate

The goal of the current work is to use the wet granulation technology to make medication tablets using fenugreek extract. Additionally, research was done on the impact of sodium starch glycolate, a super disintegrant, on drug release and disintegration. Mucilage found in fenugreek extract slows down the disintegration of tablets, resulting in a slower release of the medication. Therefore, sodium starch glycolate was employed as a super disintegrant to enhance disintegration and, consequently, in vitro drug release. Wet granulation was used to make tablet formulations both with and without sodium starch glycolate. It was done to evaluate the granules' flow characteristics and characterize the physicochemical makeup of tablet formulations. The fundamental cause of fenugreek's antidiabetic effect is the alkaloid trigonelline, which is present in large amounts. For the treatment of diabetes, this study concludes that fenugreek seed extracts in tablet form with super disintegrants will be more desirable, useful, and therapeutically more effective than combining the plant components directly for a quicker commencement of action.

Neuropathic pain is intense in nature and difficult to maintain. The main aim of this study is to provide maximum relief from pain.  The objective was to prepare bilayer tablet comprising  of pregabalin and methylcobalamin for effective treatment of neuropathic pain. Methylcobalamin was formulated as immediate release (IR) layer using super-disintegrant sodium starch glycolate (SSG) whereas pregabalin was formulated as sustained release (SR) layer using polymers hydroxypropyl methyl cellulose (HPMCK4M, K100M)  to deliver the drug at sustained manner effective for the treatment of neuropathic pain. The SR layer of pregabalin is prepared by wet granulation method and IR layer of methylcobalamin is prepared by direct compression method. Tablet blends were evaluated through various pre-compression and post-compression tests. Super disintegrant, SSG at 20% concentration produced excellent results for immediate release of methylcobalamin to exert its action and other additional beneficial effects. The K100M and K4M grade of HPMC produced excellent SR efficiency. Optimum formulation released methylcobalamin and pregabalin at 98.92%  in 45 min and 97.81% in 12 h from respective layers. Pre-compression and post-compression parameters of optimized IR layer comprising Methylcobalamin and SR layer comprising pregabalin exhibit satisfactory results. Bilayer tablet of Methylcobalamin and pregabalin prove to be effective as a combination therapy for the treatment of neuropathic pain by sequential release of the drug.

The main objective of this research work was to formulate and evaluate the bi layer tablets of chlorzoxazone by using different polymers. Chlorzoxazone is centrally acting skeletal muscle relaxant. The tablets containing immediate releasing layer and sustained release layer. The polymers used are microcrystalline cellulose pH 102, sodium starch glycol ate, croscarmellose, povidone for immediate releasing layer, HPMC K 100 cps, K4cps, E15cps, carbomer 971P, and natural gums like guar gum, Xanthan gum for sustained drug release layer. The matrix tablets were prepared by direct compression and wet granulation methods. All the excipients are tested for compatibility with drug, which revealed that there was no physical and chemical interaction occurred. The Pre formulation parameters such as bulk density, tapped density, compressibility index and Hausner’s ratio were analyzed. The In-Vitro drug release studied were Performed in the USP dissolution apparatus- (paddle) using pH 1.2 HCL buffer and pH 6.8 phosphate buffer as dissolution media at 100rpm speed and temperature of 37oC ± 5oC. The sampling was done at periodic time intervals of 1.5, 3, 4, 6, 8, 10 and 12 hours and was replaced by equal volume of dissolution media after each withdrawal. The cumulative amount of drug release at different intervals is estimated using UV method. Based on the evaluation result the formulations F6 was selected as best formulation among immediate release and is used to compress with sustained release layer. Among all formulation FB8 formulation (HPMC K100m 88%) shown maximum release of 98.84% drug in 12th hour.

  Nimodipine is an antihypertensive, calcium channel blocker, vasodilator agent and used in the treatment of various cardiovascular disorders such as angina pectoris, cardiac arrhythmia and hypertension. Oral bioavailability of Nimodipine is around 13% and having half life 9 hrs. In present research work an attempt has been made to prepare fast dissolving tablets of Nimodipine by direct compression technique with β-cyclodextrin complexes using various superdisintegrants. The powder blends were subjected for pre-compressional parameters. The prepared tablets were evaluated for post-compressional parameters. The prepared tablets were characterized by DSC and FTIR Studies. No chemical interaction between drug and excipients was confirmed by DSC and IR studies. The values of pre-compression parameters evaluated were within prescribed limits and indicated good free flowing property. All the post-compressional parameter are evaluated were prescribed limits and results were within IP acceptable limits. The tablets were evaluated for the in-vitro disintegration time and it was observed that the time for all the formulations varied from 19.24 to 48.29 sec. The promising formulations CCP4, CCC4 and CSS1 shows the 90 % of drug released within 5-8 min. Among all the formulation CCP4 (15 % crospovidone) were found to be best and showed a disintegration time of 19.24 sec, 50 % of drug released in 0.96 min, and 90 %  of drug released in 4.78 min. The stability study was conducted as per the ICH guidelines and the formulations were found to be stable, with insignificant changes in hardness, drug content and disintegration time. These results revealed that fast dissolving tablets of the poorly soluble drug, Nimodipine, showing enhanced dissolution and, hence, better patient compliance. Key words: Fast dissolving tablets, Nimodipine, sodium starch glycolate, croscarmellose sodium, crospovidone,  β-cyclodextrin.